SEC Form 4 · accession 0001209191-19-007468
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 5:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2019 | A | 9,375 | $0.00 | A | 31,616 | D | |
| Common Stock | Feb 4, 2019 | M | 3,555 | $24.47 | A | 35,171 | D | |
| Common Stock | Feb 4, 2019 | M | 1,355 | $50.51 | A | 36,526 | D | |
| Common StockF3 | Feb 4, 2019 | S | 600 | $133.1311 | D | 35,926 | D | |
| Common StockF4 | Feb 4, 2019 | S | 3,110 | $134.217 | D | 32,816 | D | |
| Common StockF5 | Feb 4, 2019 | S | 1,200 | $135.1025 | D | 31,616 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $134.63 | Feb 1, 2019 | A | 37,500 | A | — | Feb 1, 2029 | Common Stock | 37,500 | 37,500 | D |
| Stock Option (right to buy)F7 | $24.47 | Feb 4, 2019 | M | 3,555 | D | — | Mar 3, 2024 | Common Stock | 3,555 | 3,610 | D |
| Stock Option (right to buy)F8 | $50.51 | Feb 4, 2019 | M | 1,355 | D | — | Mar 1, 2026 | Common Stock | 1,355 | 37,045 | D |
Explanation of responses
- F1Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 9, 2018.
- F3The range in prices for the transaction reported on this line was $132.62 to $133.29. The average weighted price was $133.1311. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range in prices for the transaction reported on this line was $133.74 to $134.66. The average weighted price was $134.2170. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The range in prices for the transaction reported on this line was $134.91 to $135.42. The average weighted price was $135.1025. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2020 and in 36 equal monthly installments thereafter.
- F7This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
- F8This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.